Review

Men’s health 2018: BPH, prostate cancer, erectile dysfunction, supplements

Alexander Chaitoff, MPH, T. Colin Killeen, DO and Craig Nielsen, MD
Cleveland Clinic Journal of Medicine November 2018, 85 (11) 871-880; DOI: https://doi.org/10.3949/ccjm.85a.18011

This article has a correction. Please see:

ABSTRACT

This review describes the latest research and guidelines for 4 topics in men’s health commonly addressed by primary care physicians: the diagnosis and treatment of benign prostatic hyperplasia (BPH), prostate cancer, and erectile dysfunction and the evidence concerning the use of dietary supplements in men.

View Full Text

REFERENCES

  1. ↵
    1. Barry MJ,
    2. Fowler FJ Jr.,
    3. O’Leary MP, et al
    . The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 2017; 197(2S):S189–S197. doi:10.1016/j.juro.2016.10.071
    OpenUrlCrossRefPubMed
  2. ↵
    1. Urological Sciences Research Foundation
    . International Prostate Symptom Score (IPSS). http://www.usrf.org/questionnaires/AUA_SymptomScore.html. Accessed October 16, 2018.
  3. ↵
    1. McVary KT,
    2. Roehrborn CG,
    3. Avins AL, et al
    . Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 2011; 185(5):1793–1803. doi:10.1016/j.juro.2011.01.074
    OpenUrlCrossRefPubMed
  4. ↵
    1. McConnell JD,
    2. Roehrborn CG,
    3. Bautista OM, et al
    . The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349(25):2387–2398. doi:10.1056/NEJMoa030656
    OpenUrlCrossRefPubMed
  5. ↵
    1. Matsukawa Y,
    2. Takai S,
    3. Funahashi Y, et al
    . Effects of withdrawing alpha-1 blocker from the combination therapy with alpha-1 blocker and 5-alpha-reductase inhibitor in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a prospective and comparative trial using urodynamics. J Urol 2017; 198(4):905–912. doi:10.1016/j.juro.2017.05.031
    OpenUrlCrossRef
  6. ↵
    1. Barkin J,
    2. Guimaraes M,
    3. Jacobi G,
    4. Pushkar D,
    5. Taylor S,
    6. van Vierssen Trip OB
    . Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5areductase inhibitor dutasteride. Eur Urol 2003; 44(4):461–466. pmid:14499682
    OpenUrlCrossRefPubMed
  7. ↵
    1. Baldwin KC,
    2. Ginsberg PC,
    3. Roehrborn CG,
    4. Harkaway RC
    . Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology 2001; 58(2):203–209. pmid:11489700
    OpenUrlCrossRefPubMed
  8. ↵
    1. Kantor ED,
    2. Rehm CD,
    3. Haas JS,
    4. Chan AT,
    5. Giovannucci EL
    . Trends in prescription drug use among adults in the United States from 1999-2012. JAMA 2015; 314(17):1818–1831. doi:10.1001/jama.2015.13766
    OpenUrlCrossRefPubMed
  9. ↵
    1. DuBeau CE,
    2. Yalla SV,
    3. Resnick NM
    . Improving the utility of urine flow rate to exclude outlet obstruction in men with voiding symptoms. J Am Geriatr Soc 1998; 46(9):1118–1124. pmid:9736105
    OpenUrlPubMed
  10. ↵
    1. US Department of Health and Human Services Health Resources and Services Administration
    . United States Cancer Statistics: 1999–2014 Incidence and Mortality Web-Based Report. Atlanta; 2017. https://nccd.cdc.gov/uscs/. Accessed October 17, 2018.
  11. ↵
    1. US Preventive Services Task Force
    . Final recommendation statement. Prostate cancer: screening. www.uspreventiveservices-taskforce.org/Page/Document/RecommendationStatementFinal/prostate-cancer-screening1. Accessed October 16, 2018.
  12. ↵
    1. US Preventive Services Task Force
    . Archived: prostate cancer: screening. Original release date: May 2012. https://www.uspreventiveser-vicestaskforce.org/Page/Document/UpdateSummaryFinal/prostate-cancer-screening. Accessed October 16, 2018.
  13. ↵
    1. Carter HB,
    2. Albertsen PC,
    3. Barry MJ, et al
    . Early detection of prostate cancer: AUA guideline. J Urol 2013; 190(2):419–426. doi:10.1016/j.juro.2013.04.119
    OpenUrlCrossRefPubMed
  14. ↵
    1. Schröder FH,
    2. Hugosson J,
    3. Roobol MJ, et al
    . Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360(13):1320–1328. doi:10.1056/NEJMoa0810084
    OpenUrlCrossRefPubMed
  15. ↵
    1. Andriole GL,
    2. Crawford ED,
    3. Grubb RL, et al
    . Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360(13):1310–1319. doi:10.1056/NEJMoa0810696
    OpenUrlCrossRefPubMed
  16. ↵
    1. Schröder FH,
    2. Hugosson J,
    3. Carlsson S, et al
    . Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2012; 62(5):745–752. doi:10.1016/j.eururo.2012.05.068
    OpenUrlCrossRefPubMed
  17. ↵
    1. Tsodikov A,
    2. Gulati R,
    3. Heijnsdijk EAM, et al
    . Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Ann Intern Med 2017; 167(7):449–455. doi:10.7326/M16-2586
    OpenUrlCrossRef
  18. ↵
    1. Martin RM,
    2. Donovan JL,
    3. Turner EL, et al
    . Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial. JAMA 2018; 319(9):883–895. doi:10.1001/jama.2018.0154
    OpenUrlCrossRefPubMed
  19. ↵
    1. Pahwa S,
    2. Schiltz NK,
    3. Ponsky LE,
    4. Lu Z,
    5. Griswold MA,
    6. Gulani V
    . Cost-effectiveness of MR imaging–guided strategies for detection of prostate cancer in biopsy-naive men. Radiology 2017; 285(1):157–166. doi:10.1148/radiol.2017162181
    OpenUrlCrossRef
  20. ↵
    1. Ahmed HU,
    2. El-Shater Bosaily A,
    3. Brown LC, et al
    . Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 2017; 389:(10071)815–822. doi:10.1016/S0140-6736(16)32401-1
    OpenUrlCrossRefPubMed
  21. ↵
    1. Kasivisvanathan V,
    2. Rannikko AS,
    3. Borghi M, et al
    . MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 2018; 378(19):1767–1777. doi:10.1056/NEJMoa1801993
    OpenUrlCrossRefPubMed
  22. ↵
    1. Wilt TJ,
    2. Jones KM,
    3. Barry MJ, et al
    . Follow-up of prostatectomy versus observation for early prostate cancer. N Engl J Med 2017; 377(2):132–142. doi:10.1056/NEJMoa1615869
    OpenUrlCrossRefPubMed
  23. ↵
    1. Bill-Axelson A,
    2. Holmberg L,
    3. Garmo H, et al
    . Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014; 370(10):932–942. doi:10.1056/NEJMoa1311593
    OpenUrlCrossRefPubMed
  24. ↵
    1. Hamdy FC,
    2. Donovan JL,
    3. Lane JA, et al
    . 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016; 375(15):1415–1424. doi:10.1056/NEJMoa1606220.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Morley JE
    . Impotence. Am J Med 1986; 80(5):897–905. pmid:3518438
    OpenUrlCrossRefPubMed
  26. ↵
    1. NIH Consensus Development Panel on Impotence
    . NIH Consensus Conference. Impotence. JAMA 1993; 270(1):83–90. pmid:8510302
    OpenUrlCrossRefPubMed
  27. ↵
    1. Selvin E,
    2. Burnett AL,
    3. Platz EA
    . Prevalence and risk factors for erectile dysfunction in the US. Am J Med 2007; 120(2):151–157. doi:10.1016/j.amjmed.2006.06.010
    OpenUrlCrossRefPubMed
  28. ↵
    1. Rosen RC,
    2. Cappelleri JC,
    3. Gendrano N 3rd.
    . The International Index of Erectile Function (IIEF): a state-of-the-science review. Int J Impot Res 2002; 14(4):226–244. doi:10.1038/sj.ijir.3900857
    OpenUrlCrossRefPubMed
  29. ↵
    1. Gandaglia G,
    2. Briganti A,
    3. Jackson G, et al
    . A systematic review of the association between erectile dysfunction and cardiovascular disease. Eur Urol 2014; 65(5):968–978. doi:10.1016/j.eururo.2013.08.023
    OpenUrlCrossRefPubMed
  30. ↵
    1. Heaton JPW,
    2. Adams MA
    . Causes of erectile dysfunction. Endocrine 2004; 23(2-3):119–123. doi:10.1385/ENDO:23:2-3:119
    OpenUrlCrossRef
  31. ↵
    1. Montorsi F,
    2. Salonia A,
    3. Deho F, et al
    . Pharmacological management of erectile dysfunction. BJU Int 2003; 91(5):446–454. pmid:12603396
    OpenUrlCrossRefPubMed
  32. ↵
    1. Cai X,
    2. Tian Y,
    3. Wu T,
    4. Cao CX,
    5. Bu SY,
    6. Wang KJ
    . The role of statins in erectile dysfunction: a systematic review and meta-analysis. Asian J Androl 2014; 16(3):461–466. doi:10.4103/1008-682X.123678
    OpenUrlCrossRef
  33. ↵
    1. Webb DJ,
    2. Freestone S,
    3. Allen MJ,
    4. Muirhead GJ
    . Sildenafil citrate and blood-pressure–lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol 1999; 83(5):21C–28C. pmid:10078539
    OpenUrlPubMed
  34. ↵
    1. Doggrell SA
    . Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction. Expert Opin Pharmacother 2005; 6(1):75–84. doi:10.1517/14656566.6.1.75
    OpenUrlCrossRefPubMed
  35. ↵
    1. Gresser U,
    2. Gleiter CH
    . Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil—review of the literature. Eur J Med Res 2002; 7(10):435–446. pmid:12435622
    OpenUrlPubMed
  36. ↵
    1. Eardley I,
    2. Mirone V,
    3. Montorsi F, et al
    . An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy. BJU Int 2005; 96(9):1323–1332. doi:10.1111/j.1464-410X.2005.05892.x
    OpenUrlCrossRefPubMed
  37. ↵
    1. von Keitz A,
    2. Rajfer J,
    3. Segal S, et al
    . A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil. Eur Urol 2004; 45(4):499–509. doi:10.1016/j.eururo.2003.11.030
    OpenUrlCrossRefPubMed
  38. ↵
    1. Martin-Morales A,
    2. Haro JM,
    3. Beardsworth A,
    4. Bertsch J,
    5. Kontodimas S; EDOS Group
    . Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS). Eur Urol 2007; 51(2):541–550. doi:10.1016/j.eururo.2006.09.027
    OpenUrlCrossRefPubMed
  39. ↵
    1. Yuan J,
    2. Zhang R,
    3. Yang Z, et al
    . Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol 2013; 63(5):902–912. doi:10.1016/j.eururo.2013.01.012
    OpenUrlCrossRefPubMed
  40. ↵
    1. Cao S,
    2. Yin X,
    3. Wang Y,
    4. Zhou H,
    5. Song F,
    6. Lu Z
    . Smoking and risk of erectile dysfunction: systematic review of observational studies with meta-analysis. PLoS One 2013; 8(4):e60443. doi:10.1371/journal.pone.0060443
    OpenUrlCrossRefPubMed
  41. ↵
    1. Derby CA,
    2. Mohr BA,
    3. Goldstein I,
    4. Feldman HA,
    5. Johannes CB,
    6. McKin-lay JB
    . Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology 2000; 56(2):302–306. pmid:10925098
    OpenUrlCrossRefPubMed
  42. ↵
    1. Esposito K,
    2. Giugliano F,
    3. Di Palo C, et al
    . Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 2004; 291(24):2978–2984. doi:10.1001/jama.291.24.2978
    OpenUrlCrossRefPubMed
  43. ↵
    1. Schmidt HM,
    2. Munder T,
    3. Gerger H,
    4. Frühauf S,
    5. Barth J
    . Combination of psychological intervention and phosphodiesterase-5 inhibitors for erectile dysfunction: a narrative review and meta-analysis. J Sex Med 2014; 11(6):1376–1391. doi:10.1111/jsm.12520
    OpenUrlCrossRefPubMed
  44. ↵
  45. ↵
    1. Labre MP
    . Burn fat, build muscle: a content analysis of men’s health and men’s fitness. Int J Mens Health 2005; 4(2):187–200.
    OpenUrl
  46. ↵
    1. Qato DM,
    2. Alexander GC,
    3. Conti RM,
    4. Johnson M,
    5. Schumm P,
    6. Lindau ST
    . Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 2008; 300(24):2867–2878. doi:10.1001/jama.2008.892
    OpenUrlCrossRefPubMed
  47. ↵
    1. Park SY,
    2. Murphy SP,
    3. Wilkens LR,
    4. Henderson BE,
    5. Kolonel LN
    . Multivitamin use and the risk of mortality and cancer incidence: the multiethnic cohort study. Am J Epidemiol 2011; 173(8):906–914. doi:10.1093/aje/kwq447
    OpenUrlCrossRefPubMed
  48. ↵
    1. McNeill G,
    2. Avenell A,
    3. Campbell MK, et al
    . Effect of multivitamin and multimineral supplementation on cognitive function in men and women aged 65 years and over: a randomised controlled trial. Nutr J 2007; 6(1):10. doi:10.1186/1475-2891-6-10
    OpenUrlCrossRefPubMed
  49. ↵
    1. Harris E,
    2. Macpherson H,
    3. Vitetta L,
    4. Kirk J,
    5. Sali A,
    6. Pipingas A
    . Effects of a multivitamin, mineral and herbal supplement on cognition and blood biomarkers in older men: a randomised, placebo-con-trolled trial. Hum Psychopharmacol Clin Exp 2012; 27(4):370–377. doi:10.1002/hup.2236
    OpenUrlCrossRefPubMed
  50. ↵
    1. Vivekananthan DP,
    2. Penn MS,
    3. Sapp SK,
    4. Hsu A,
    5. Topol EJ
    . Use of anti-oxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet 2003; 361(9374):2017–2023. doi:10.1016/S0140-6736(03)13637-9
    OpenUrlCrossRefPubMed
  51. ↵
    1. Miller ER,
    2. Pastor-Barriuso R,
    3. Dalal D,
    4. Riemersma RA,
    5. Appel LJ,
    6. Guallar E
    . Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142(1):37–46. pmid:15537682
    OpenUrlCrossRefPubMed
  52. ↵
    1. Bjelakovic G,
    2. Nikolova D,
    3. Gluud LL,
    4. Simonetti RG,
    5. Gluud C
    . Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 2007; 297(8):842–857. doi:10.1001/jama.297.8.842
    OpenUrlCrossRefPubMed
  53. ↵
    1. Grey A,
    2. Bolland M
    . Clinical trial evidence and use of fish oil supplements. JAMA Intern Med 2014; 174(3):460–462. doi:10.1001/jamainternmed.2013.12765
    OpenUrlCrossRefPubMed
  54. ↵
    1. Cui T,
    2. Kovell RC,
    3. Brooks DC,
    4. Terlecki RP
    . A urologist’s guide to ingredients found in top-selling nutraceuticals for men’s sexual health. J Sex Med 2015; 12(11):2105–2117. doi:10.1111/jsm.13013
    OpenUrlCrossRef
  55. ↵
    1. Schenk JM,
    2. Till CA,
    3. Tangen CM, et al
    . Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the Prostate Cancer Prevention Trial. Cancer Epidemiol Prev Biomarkers 2014; 23(8):1484–1493. doi:10.1158/1055-9965.EPI-13-1340
    OpenUrlCrossRef
  56. ↵
    1. Albanes D,
    2. Mondul AM,
    3. Yu K, et al
    . Serum 25-hydroxy vitamin D and prostate cancer risk in a large nested case-control study. Cancer Epidemiol Prev Biomarkers 2011; 20(9):1850–1860. doi:10.1158/1055-9965.EPI-11-0403
    OpenUrlAbstract/FREE Full Text
  57. ↵
    1. Roswall N,
    2. Larsen SB,
    3. Friis S, et al
    . Micronutrient intake and risk of prostate cancer in a cohort of middle-aged, Danish men. Cancer Causes Control 2013; 24(6):1129–1135. doi:10.1007/s10552-013-0190-4
    OpenUrlCrossRefPubMed
  58. ↵
    1. Mondul AM,
    2. Watters JL,
    3. Männistö S, et al
    . Serum retinol and risk of prostate cancer. Am J Epidemiol 2011; 173(7):813–821. doi:10.1093/aje/kwq429
    OpenUrlCrossRefPubMed
  59. ↵
    1. Schenk JM,
    2. Riboli E,
    3. Chatterjee N, et al
    . Serum retinol and prostate cancer risk: a nested case-control study in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Prev Biomarkers 2009; 18(4):1227–1231. doi:10.1158/1055-9965.EPI-08-0984
    OpenUrlCrossRef
  60. ↵
    1. Bidoli E,
    2. Talamini R,
    3. Zucchetto A, et al
    . Dietary vitamins E and C and prostate cancer risk. Acta Oncol 2009; 48(6):890–894. doi:10.1080/02841860902946546
    OpenUrlCrossRefPubMed
  61. ↵
    1. Wright ME,
    2. Weinstein SJ,
    3. Lawson KA, et al
    . Supplemental and dietary vitamin E intakes and risk of prostate cancer in a large prospective study. Cancer Epidemiol Prev Biomarkers 2007; 16(6):1128–1135. doi:10.1158/1055-9965.EPI-06-1071
    OpenUrlCrossRef
  62. ↵
    1. Klein EA,
    2. Thompson IM,
    3. Tangen CM, et al
    . Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011; 306(14):1549–1556. doi:10.1001/jama.2011.1437
    OpenUrlCrossRefPubMed
  63. ↵
    1. Jingwi EY,
    2. Abbas M,
    3. Ricks-Santi L, et al
    . Vitamin D receptor genetic polymorphisms are associated with PSA level, Gleason score and prostate cancer risk in African-American men. Anticancer Res 2015; 35(3):1549–1558. pmid:25750310
    OpenUrlAbstract/FREE Full Text
  64. ↵
    1. Siddiqui IA,
    2. Asim M,
    3. Hafeez BB,
    4. Adhami VM,
    5. Tarapore RS,
    6. Mukhtar H
    . Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer. FASEB J 2011; 25(4):1198–1207. doi:10.1096/fj.10-167924
    OpenUrlCrossRefPubMed
  65. ↵
    1. Yacoubian A,
    2. Dargham RA,
    3. Khauli RB,
    4. Bachir BG
    . Overview of dietary supplements in prostate cancer. Curr Urol Rep 2016; 17(11):78. doi:10.1007/s11934-016-0637-8
    OpenUrlCrossRef
  66. ↵
    1. Kallifatidis G,
    2. Hoy JJ,
    3. Lokeshwar BL
    . Bioactive natural products for chemoprevention and treatment of castration-resistant prostate cancer. Semin Cancer Biol 2016; 40:160–169. doi:10.1016/j.semcancer.2016.06.003
    OpenUrlCrossRef
  67. ↵
    1. Shui IM,
    2. Mondul AM,
    3. Lindström S, et al
    . Circulating vitamin D, vitamin D–related genetic variation, and risk of fatal prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer 2015; 121(12):1949–1956. doi:10.1002/cncr.29320
    OpenUrlCrossRefPubMed
  68. ↵
    1. Tacklind J,
    2. MacDonald R,
    3. Rutks I,
    4. Stanke JU,
    5. Wilt TJ
    . Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2012; 12:CD001423. doi:10.1002/14651858.CD001423.pub3
    OpenUrlCrossRefPubMed
  69. ↵
    1. Wandel S,
    2. Jüni P,
    3. Tendal B, et al
    . Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ 2010; 341:c4675. doi:10.1136/bmj.c4675
    OpenUrlAbstract/FREE Full Text
  70. ↵
    1. Reinhart KM,
    2. Coleman CI,
    3. Teevan C,
    4. Vachhani P,
    5. White CM
    . Effects of garlic on blood pressure in patients with and without systolic hyper-tension: a meta-analysis. Ann Pharmacother 2008; 42(12):1766–1771. doi:10.1345/aph.1L319
    OpenUrlCrossRefPubMed
  71. ↵
    1. Wang J,
    2. Zhang X,
    3. Lan H,
    4. Wang W
    . Effect of garlic supplement in the management of type 2 diabetes mellitus (T2DM): a meta-analysis of randomized controlled trials. Food Nutr Res 2017; 61(1):1377571. doi:10.1080/16546628.2017.1377571
    OpenUrlCrossRef

This article requires you to have a ccjm.org account to view the full text. If you already have an account, you may log in below to view this article along with all other CCJM content. If you do not have an account, register here. It’s free!

Back to top

Registration is Now Required for Free Access to CCJM Content

Register once and log in for full access to articles and content. Click “Register” in the upper right corner and follow the simple instructions to create a new account.

If you are using a mobile device, click on the settings icon to access the Register link.

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Subjects